Automate Your Wheel Strategy on PFE
With Tiblio's Option Bot, you can configure your own wheel strategy including PFE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PFE
- Rev/Share 11.044
- Book/Share 16.3757
- PB 1.5527
- Debt/Equity 0.665
- CurrentRatio 1.2822
- ROIC 0.1065
- MktCap 144109375042.0
- FreeCF/Share 1.8252
- PFCF 13.8887
- PE 14.6718
- Debt/Assets 0.2957
- DivYield 0.0679
- ROE 0.1091
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 5
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | PFE | UBS | -- | Neutral | -- | $25 | Jan. 7, 2026 |
| Resumed | PFE | Citigroup | -- | Neutral | -- | $26 | Dec. 2, 2025 |
| Initiation | PFE | Scotiabank | -- | Sector Outperform | -- | $30 | Nov. 13, 2025 |
| Initiation | PFE | Cantor Fitzgerald | -- | Neutral | -- | $24 | April 22, 2025 |
| Resumed | PFE | BofA Securities | -- | Neutral | -- | $29 | Dec. 10, 2024 |
| Initiation | PFE | Bernstein | -- | Market Perform | -- | $32 | Oct. 17, 2024 |
News
Trump, Pfizer to announce agreement to lower Medicaid drug prices
Published: September 30, 2025 by: CNBC Television
Sentiment: Positive
President Donald Trump on Tuesday will announce an agreement with Pfizer to voluntarily sell its medications for less, as his administration pushes to link U.S. drug prices to cheaper ones abroad, CNBC's Angelica Peebles reports.
Read More
President Trump to announce drug-pricing deal with Pfizer
Published: September 30, 2025 by: CNBC Television
Sentiment: Positive
CNBC's Eamon Javers joins 'Squawk on the Street' with the latest news.
Read More
Metsera Posts Promising Weight-Loss Drug Results. It Could Be a Win for Pfizer.
Published: September 30, 2025 by: Barrons
Sentiment: Positive
Pfizer said last week it would pay $47.50 per share for Metsera, and an extra $22.50 per share if its drugs hit certain milestones.
Read More
Trump, Pfizer to announce agreement to lower drug prices
Published: September 30, 2025 by: CNBC
Sentiment: Positive
President Donald Trump will announce an agreement with Pfizer to voluntarily sell its medications at lower prices, as his administration pushes to link U.S. drug prices to the cheaper prices paid abroad. In this article PFE
Read More
White House to Announce ‘TrumpRx' Drug-Buying Website, and Deal With Pfizer
Published: September 30, 2025 by: WSJ
Sentiment: Positive
President Trump is expected to unveil the measures with Pfizer's CEO on Tuesday
Read More
Trump to announce deal with Pfizer to sell drugs at lower prices, Washington Post reports
Published: September 30, 2025 by: Reuters
Sentiment: Positive
U.S. President Donald Trump will announce an agreement with Pfizer on Tuesday to voluntarily sell the company's medications through Medicaid at lower prices, the Washington Post reported on Tuesday, citing sources.
Read More
Pfizer Is Likely To Pass The Drug Import Tariff Stress Test
Published: September 29, 2025 by: Seeking Alpha
Sentiment: Positive
President Trump's new 100% tariff on imported drugs creates a major new risk for the pharma sector. While competitors announce flashy, multi-billion-dollar U.S. investment plans, Pfizer appears vague in comparison. We argue this perception is misleading and overlooks the company's core strategic advantage. A deep dive into Pfizer's existing manufacturing footprint and management's plan to onshore new technologies reveals a powerful and underappreciated case for a tariff exemption.
Read More
3 Of My Favorite Biotech Stocks Under $10
Published: September 29, 2025 by: Seeking Alpha
Sentiment: Positive
Today, I am highlighting three biotech stocks I like in the current market that are trading at under $10.00 a share. The options on these stocks are also lucrative and liquid, making them well-suited for consistent covered call trades. Covered call strategies offer downside protection in the underperforming, high-beta biotech sector, supporting a rinse, wash, and repeat approach.
Read More
Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock
Published: September 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Hearing Against Pfizer Set For 29 September In Contraceptive ‘Depo-Provera' Multidistrict Litigation Overseen By Levin Papantonio
Published: September 25, 2025 by: Business Wire
Sentiment: Neutral
PENSACOLA, Fla.--(BUSINESS WIRE)--A hearing in the Depo-Provera legal action against Pfizer Inc. (NYSE:PFE) will take place on Monday, 29 September at 9:00am CT in the United States Courthouse in Pensacola, Florida. The hearing will address oral arguments from the plaintiffs and defendants concerning the issue of pre-emption. The pre-emption defence is common in drug litigation. It involves the drug manufacturer arguing that they cannot be sued for failure to warn under state law, because chang.
Read More
Pfizer: Invest For The Yield, Not The Weight-Loss Drug Chase
Published: September 25, 2025 by: Seeking Alpha
Sentiment: Positive
Pfizer Inc. is acquiring Metsera for up to $7.2 billion, aiming to enter the weight-loss drug market despite late-stage entry and no ongoing Phase 3 trials. PFE's acquisition targets GLP-1-based obesity drugs but faces stiff competition from established players like Eli Lilly and Novo Nordisk and promising biotechs like Viking Therapeutics. The stock offers a compelling 7% dividend yield, supported by cost-saving initiatives and stable oncology/vaccine growth, despite declining Covid vaccine sales.
Read More
Can PFE Successfully Return to the Obesity Space With Metsera Buyout?
Published: September 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Pfizer strikes a $4.9B deal for Metsera, adding obesity drug candidates to its pipeline after scrapping danuglipron.
Read More
Pfizer's Metsera buy raises competitive heat for Novo Nordisk
Published: September 23, 2025 by: Proactive Investors
Sentiment: Negative
UBS has warned that Pfizer Inc's (NYSE:PFE, ETR:PFE) $7.3 billion acquisition of Metsera will sharpen competition for Novo Nordisk (NYSE:NVO) in the fast-growing obesity drug market, particularly towards the end of the decade. The bank kept its 'neutral' rating on Novo shares with a DKr340 price target, implying 12.5% downside from the current level.
Read More
Pfizer bets $7.3 billion on obesity drugs with Metsera buy
Published: September 22, 2025 by: Fast Company
Sentiment: Positive
Pfizer is fattening its drug portfolio by betting that more people will want to slim down. The New York drugmaker announced Monday that it's acquiring Metsera, and its portfolio of four medications for obesity and cardiometabolic diseases, in a deal valued at as much as $7.3 billion.
Read More
Pfizer Inc. (PFE) M&A Call Transcript
Published: September 22, 2025 by: Seeking Alpha
Sentiment: Neutral
Pfizer Inc. (NYSE:PFE ) M&A Call September 22, 2025 8:00 AM EDT Company Participants Francesca DeMartino - Chief Investor Relations Officer Chris Boshoff - Chief Scientific Officer and President of Research & Development Andrew Baum - Chief Strategy & Innovation Officer, Executive VP Jim List Conference Call Participants Mohit Bansal - Wells Fargo Securities, LLC, Research Division David Risinger - Leerink Partners LLC, Research Division Evan Seigerman - BMO Capital Markets Equity Research Umer Raffat - Evercore ISI Institutional Equities, Research Division Kerry Holford - Joh. Berenberg, Gossler & Co. KG, Research Division Christopher Schott - JPMorgan Chase & Co, …
Read More
Johnson Fistel Investigates Fairness of Proposed Sale of Metsera
Published: September 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP, has launched an investigation into whether the board members of Metsera, Inc. (NASDAQ: MTSR) breached their fiduciary duties in connection with the proposed sale of the Company to Pfizer, Inc. (NYSE: PFE).
Read More
Pfizer Stock Higher on Multi-Billion Dollar Metsera Buyout
Published: September 22, 2025 by: Schaeffers Research
Sentiment: Positive
Pfizer Inc (NYSE:PFE) stock is up 2.6% to trade at $24.65 at last check, after the pharma giant revealed it will buy weight-loss drug company Metsera (MTSR) in a deal valued up to $7.3 billion.
Read More
Pfizer acquires Metsera in $7.3B deal to boost obesity drug pipeline
Published: September 22, 2025 by: Proactive Investors
Sentiment: Positive
Pfizer Inc (NYSE:PFE, ETR:PFE) on Monday announced that it will acquire Metsera, Inc (NASDAQ: MTSR), a weight-loss drug developer, in a deal valued at up to $7.3 billion, or $47.50 per share in cash. Metsera is also eligible to receive an additional $22.50 per share contingent on the achievement of certain performance milestones.
Read More
Pfizer Jumps Into Weight-Loss Drug Segment With $7.3 Billion Metsera Deal
Published: September 22, 2025 by: Investopedia
Sentiment: Positive
Metsera (MTSR) shares skyrocketed 60% in premarket trading after Pfizer (PFE) agreed to purchase the biopharma firm for up to $7.3 billion to jump into the lucrative weight-loss drug segment. Shares of Pfizer were up slightly.
Read More
Pfizer Tries To Revitalize Obesity Portfolio With $5 Billion Matsera Deal
Published: September 22, 2025 by: Benzinga
Sentiment: Positive
Pfizer Inc. PFE on Monday agreed to acquire Metsera, Inc. MTSR to accelerate the next generation of medicines for obesity and cardiometabolic diseases.
Read More
Mizuho's Jared Holz: There's not much value left in vaccine stocks
Published: September 19, 2025 by: CNBC Television
Sentiment: Negative
Jared Holz, Mizuho healthcare senior strategist, joins CNBC's 'Squawk on the Street' to discuss outlooks on pharmaceuticals, what new government vaccine panel recommendations mean for the stocks, and much more.
Read More
PFE vs. AZN: Which Cancer-Focused Drug Giant Is the Better Pick?
Published: September 19, 2025 by: Zacks Investment Research
Sentiment: Negative
AstraZeneca and Pfizer both boast strong oncology pipelines, but growth paths, dividends and challenges set them apart for investors.
Read More
COVID-19 Vaccine Stocks Fall on Reports Linking Shots to Child Deaths
Published: September 15, 2025 by: Zacks Investment Research
Sentiment: Negative
MRNA, BNTX, PFE and NVAX stocks fall as health officials reportedly plan to link COVID-19 vaccines to child deaths ahead of a key CDC meeting.
Read More
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
Published: September 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Meet 16 Ideal "Safer" September Dividend Dogs Of The S&P500
Published: September 12, 2025 by: Seeking Alpha
Sentiment: Positive
Sixteen of the thirty-eight highest-yield, 'safer' S&P 500 dividend stocks are highlighted as ready to buy, with adequate free cash flow supporting payouts. Analyst forecasts suggest top ten S&P 500 dividend 'dogs' could deliver 20.45% to 38.5% net gains by September 2026, with an average gain of 27.35%. Stocks like Amcor, Healthpeak, Conagra, Pfizer, and Verizon offer the best combination of high yield and low price, following the O'Higgins 'Dogs of the Dow' strategy.
Read More
COVID vaccine makers' shares fall as Trump officials to link shots to child deaths, report says
Published: September 12, 2025 by: Market Watch
Sentiment: Negative
Shares of companies that make COVID vaccines sank Friday, after a report raised fears that Trump administration health officials will blame the vaccines for some child deaths.
Read More
Pfizer, Moderna shares fall on report that Trump officials will link child deaths to Covid shots
Published: September 12, 2025 by: CNBC
Sentiment: Negative
Shares of Pfizer and Moderna fell on Friday after a report that Trump administration health officials plan to link Covid vaccines to the deaths of 25 children. The report comes as Health and Human Services Secretary Robert F.
Read More
Pfizer's Late-Stage Pipeline Fuels Long-Term Growth Prospects
Published: September 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Pfizer's late-stage pipeline, from oncology blockbusters to mRNA vaccines, positions it for long-term growth despite recent setbacks.
Read More
Pfizer's Comeback Accelerates
Published: September 11, 2025 by: Seeking Alpha
Sentiment: Positive
Pfizer achieved 10% year-over-year Q2 2025 revenue growth to $14.7 billion, driven by Abrysvo RSV vaccine and Seagen-acquired oncology assets. Management expects over $20 billion in risk-adjusted revenue from new launches by 2030, offsetting $17–$20 billion in patent expirations. R&D investment of ~$11 billion in 2025 supports 28 Phase 3 programs across oncology, vaccines, inflammation, and rare diseases.
Read More
5 Large Drug Stocks to Watch Despite Industry & Macro Headwinds
Published: September 10, 2025 by: Zacks Investment Research
Sentiment: Negative
In the Large-Cap Pharmaceuticals industry, Lilly, J&J, Novartis, Pfizer and Bayer are worth retaining amid macro pressure and rising innovation.
Read More
About Pfizer Inc. (PFE)
- IPO Date 1972-06-01
- Website https://www.pfizer.com
- Industry Drug Manufacturers - General
- CEO Albert Bourla
- Employees 81000